Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
763.04
+1.19 (0.16%)
At close: Apr 6, 2026, 4:00 PM EDT
758.86
-4.18 (-0.55%)
After-hours: Apr 6, 2026, 7:02 PM EDT
Regeneron Pharmaceuticals Stock Forecast
Stock Price Forecast
The 25 analysts that cover Regeneron Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $821.08, which forecasts a 7.61% increase in the stock price over the next year. The lowest target is $587 and the highest is $1,057.
Price Target: $821.08 (+7.61%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Regeneron Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 8 | 8 | 9 | 9 | 9 |
| Buy | 9 | 8 | 7 | 8 | 7 | 9 |
| Hold | 5 | 6 | 7 | 7 | 6 | 6 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 21 | 23 | 23 | 25 | 23 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $875 | Buy | Initiates | $875 | +14.67% | Mar 31, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $818 → $801 | Strong Buy | Maintains | $818 → $801 | +4.97% | Mar 31, 2026 |
| Barclays | Barclays | Buy Initiates $923 | Buy | Initiates | $923 | +20.96% | Mar 6, 2026 |
| RBC Capital | RBC Capital | Hold Maintains $745 → $765 | Hold | Maintains | $745 → $765 | +0.26% | Mar 2, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $865 → $975 | Strong Buy | Maintains | $865 → $975 | +27.78% | Feb 9, 2026 |
Financial Forecast
Revenue This Year
16.05B
from 14.34B
Increased by 11.88%
Revenue Next Year
17.70B
from 16.05B
Increased by 10.31%
EPS This Year
46.75
from 41.48
Increased by 12.71%
EPS Next Year
54.83
from 46.75
Increased by 17.27%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 18.4B | 19.6B | |||
| Avg | 16.0B | 17.7B | |||
| Low | 14.4B | 15.8B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 28.0% | 22.3% | |||
| Avg | 11.9% | 10.3% | |||
| Low | 0.3% | -1.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 61.62 | 66.32 | |||
| Avg | 46.75 | 54.83 | |||
| Low | 36.39 | 45.37 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 48.6% | 41.8% | |||
| Avg | 12.7% | 17.3% | |||
| Low | -12.3% | -2.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.